Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in young adults with early-onset obesity
2019-002274-31Phase 4Active
- Sponsor
- Department of Biomedical Sciences, University of Copenhagen
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Semaglutide with Placebo (2 arms). Primary endpoint: Change in BMI. Started Jul 2020; status: active.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2019-002274-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002274-31.